Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxytocin Nasal Spray for Social Affiliation in Schizophrenia Spectrum
NCT00663039Phase 2Completed
- Sponsor
- University of Maryland, Baltimore
- Start
- Oct 2009
- Primary completion
- Jul 2015
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of oxytocin nasal spray in schizophrenia spectrum and other psychotic disorders (2 arms), sponsored by University of Maryland, Baltimore. Primary endpoint: Social Affiliation Measured by Social Affiliative Role Play at 30 minutes. Started Oct 2009; status: completed.
02
Drugs
oxytocin nasal spray
03
Conditions
schizophrenia spectrum and other psychotic disorders
Beyond the preview
Go deeper on NCT00663039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00663039.